Cannabics Pharmaceuticals Stock Probability of Future Pink Sheet Price Finishing Under 0.0135
| CNBX Stock | USD 0.01 0 12.00% |
Cannabics |
Cannabics Pharmaceuticals Target Price Odds to finish below 0.0135
The tendency of Cannabics Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 0.01 after 90 days |
| 0.01 | 90 days | 0.01 | close to 99 |
Based on a normal probability distribution, the odds of Cannabics Pharmaceuticals to stay under $ 0.01 after 90 days from now is close to 99 (This Cannabics Pharmaceuticals probability density function shows the probability of Cannabics Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Cannabics Pharmaceuticals price to stay between its current price of $ 0.01 and $ 0.01 at the end of the 90-day period is under 95 .
Given the investment horizon of 90 days Cannabics Pharmaceuticals has a beta of 0.0896 suggesting as returns on the market go up, Cannabics Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cannabics Pharmaceuticals will be expected to be much smaller as well. Additionally Cannabics Pharmaceuticals has an alpha of 0.8962, implying that it can generate a 0.9 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cannabics Pharmaceuticals Price Density |
| Price |
Predictive Modules for Cannabics Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cannabics Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cannabics Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cannabics Pharmaceuticals is not an exception. The market had few large corrections towards the Cannabics Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cannabics Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cannabics Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.90 | |
β | Beta against Dow Jones | 0.09 | |
σ | Overall volatility | 0.0007 | |
Ir | Information ratio | 0.12 |
Cannabics Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cannabics Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cannabics Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cannabics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cannabics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cannabics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Cannabics Pharmaceuticals currently holds 1.6 M in liabilities with Debt to Equity (D/E) ratio of 0.48, which is about average as compared to similar companies. Cannabics Pharmaceuticals has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cannabics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cannabics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cannabics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cannabics to invest in growth at high rates of return. When we think about Cannabics Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.72 M) with profit before overhead, payroll, taxes, and interest of 7.16 K. | |
| Cannabics Pharmaceuticals currently holds about 96.28 K in cash with (1.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of Cannabics Pharmaceuticals shares are held by company insiders |
Cannabics Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cannabics Pink Sheet often depends not only on the future outlook of the current and potential Cannabics Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cannabics Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.3 M |
Cannabics Pharmaceuticals Technical Analysis
Cannabics Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Cannabics Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cannabics Pharmaceuticals. In general, you should focus on analyzing Cannabics Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Cannabics Pharmaceuticals Predictive Forecast Models
Cannabics Pharmaceuticals' time-series forecasting models is one of many Cannabics Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cannabics Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Cannabics Pharmaceuticals
Checking the ongoing alerts about Cannabics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cannabics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cannabics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cannabics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cannabics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Cannabics Pharmaceuticals currently holds 1.6 M in liabilities with Debt to Equity (D/E) ratio of 0.48, which is about average as compared to similar companies. Cannabics Pharmaceuticals has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cannabics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cannabics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cannabics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cannabics to invest in growth at high rates of return. When we think about Cannabics Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.72 M) with profit before overhead, payroll, taxes, and interest of 7.16 K. | |
| Cannabics Pharmaceuticals currently holds about 96.28 K in cash with (1.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of Cannabics Pharmaceuticals shares are held by company insiders |
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.